Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fyteko is currently overseeing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner, LIU, SUE XU, and is located within 1 distinct art unit. This represents a focused prosecution profile, where all active engagement with the USPTO is channeled through a single point of contact. The concentration in 1 distinct art unit suggests that the technology being patented falls into a specific niche within the broader Biotechnology & Pharmaceuticals field.
LIU, SUE XU is the busiest examiner for this portfolio, currently managing 1 pending office action. Because there is only 1 pending office action in the entire portfolio, this examiner's role is central to the company's immediate patent goals. For practitioners, this means that the strategy is entirely dependent on the feedback from LIU, SUE XU. There are no other pending actions or examiners to provide a comparative baseline for prosecution within this technology area. Success for Fyteko in this instance relies on successfully addressing the specific concerns raised in the 1 pending office action within its designated art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, SUE XU | 1 | 20.9% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18398708 | BIOACTIVE COMPOSITION FOR IMPROVING STRESS TOLERANCE OF PLANTS | LIU, SUE XU | 3d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18398708 | BIOACTIVE COMPOSITION FOR IMPROVING STRESS TOLERANCE OF PLANTS | LIU, SUE XU | 3d overdue |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18398708 | BIOACTIVE COMPOSITION FOR IMPROVING STRESS TOLERANCE OF PLANTS | LIU, SUE XU | 1616 | §103DP | Final Rejection | 3d overdue | Pending | Dec 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial